Her fund funded Cognate, and on the buyout took the spinoff which preserved the data and know how and rights from Cognate to ensure approval. But Advent otherwise is a service company without any tangible assets and very few IP rights and none in DCVax-L. It has a contract and of course all of that is moot now that it will be rolled into NWBO, but keeping that operating cost and risk which is also a necessary predicate for approval, having an operating, licensed and certified facility which it was contracted to run. Now consolidation suggests the separation of that risk is no longer necessary, which rather than suggesting a failure, suggests they anticipate success, as I see it.
We all have our opinions.
Market Data 
Markets 
AI
